Marty
Well-known member
Betrixaban bests warfarin at lower doses in Phase II study.
Bloomberg News (3/16, Pettypiece) reports that "Merck & Co. and Portola Pharmaceuticals, Inc.'s experimental anti-clotting drug betrixaban caused less bleeding than an older treatment in people with an irregular heartbeat, a study found." Researchers presenting the study at the American College of Cardiology conference on Monday noted that "patients with atrial fibrillation had fewer incidents of bleeding when taking the lowest dose of betrixaban than those given warfarin." Meanwhile, "bleeding rates at the higher doses of betrixaban were similar to warfarin."
The San Francisco Business Times (3/15, Leuty) noted that "the 508-patient Phase II study" was "conducted at 35 centers in the United States, Canada, and Germany." The "40-milligram dose of betrixaban on 127 patients demonstrated less major and fewer non-major bleeding incidences than 127 patients on warfarin."
Bloomberg News (3/16, Pettypiece) reports that "Merck & Co. and Portola Pharmaceuticals, Inc.'s experimental anti-clotting drug betrixaban caused less bleeding than an older treatment in people with an irregular heartbeat, a study found." Researchers presenting the study at the American College of Cardiology conference on Monday noted that "patients with atrial fibrillation had fewer incidents of bleeding when taking the lowest dose of betrixaban than those given warfarin." Meanwhile, "bleeding rates at the higher doses of betrixaban were similar to warfarin."
The San Francisco Business Times (3/15, Leuty) noted that "the 508-patient Phase II study" was "conducted at 35 centers in the United States, Canada, and Germany." The "40-milligram dose of betrixaban on 127 patients demonstrated less major and fewer non-major bleeding incidences than 127 patients on warfarin."